论文部分内容阅读
目的观察分析厄贝沙坦氢氯噻嗪与福辛普利治疗原发性高血压的临床疗效。方法选择80例原发性高血压患者作为本次观察对象,时间为2010年9月至2015年4月,将80例原发性高血压患者随机分成两组,对照组40例患者采用福辛普利进行治疗,实验组40例患者采用厄贝沙坦氢氯噻嗪进行治疗,观察两组原发性高血压患者治疗前后血压变化情况及不良反应发生率。结果实验组原发性高血压患者不良反应发生率(5.00%)明显低于对照组(17.50%),且两组原发性高血压患者治疗后血压情况存在显著差异(P<0.05),统计学有意义。结论针对原发性高血压患者采用厄贝沙坦氢氯噻嗪治疗的临床疗效优于福辛普利,且安全可靠,无明显不良反应出现。
Objective To observe the clinical efficacy of irbesartan hydrochlorothiazide and fosinopril in the treatment of essential hypertension. Methods Eighty patients with essential hypertension were selected as the observation object from September 2010 to April 2015. Eighty patients with essential hypertension were randomly divided into two groups. Forty patients in the control group were treated with Fusin Puli for treatment, experimental group of 40 patients treated with irbesartan hydrochlorothiazide for observation of two groups of patients with essential hypertension before and after treatment of blood pressure changes and the incidence of adverse reactions. Results The incidence of adverse reactions (5.00%) in patients with essential hypertension in the experimental group was significantly lower than that in the control group (17.50%). There was significant difference in the blood pressure after treatment between the two groups of patients with essential hypertension (P <0.05) Learning makes sense. Conclusion The clinical efficacy of irbesartan hydrochloride in patients with essential hypertension is better than that of fosinopril, and safe and reliable, no obvious adverse reactions.